Vyne Therapeutics Inc
NASDAQ:VYNE

Watchlist Manager
Vyne Therapeutics Inc Logo
Vyne Therapeutics Inc
NASDAQ:VYNE
Watchlist
Price: 0.562 USD -4.42% Market Closed
Market Cap: 18.7m USD

Wall Street
Price Targets

VYNE Price Targets Summary
Vyne Therapeutics Inc

Wall Street analysts forecast VYNE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VYNE is 3.315 USD with a low forecast of 2.02 USD and a high forecast of 4.725 USD.

Lowest
Price Target
2.02 USD
259% Upside
Average
Price Target
3.315 USD
490% Upside
Highest
Price Target
4.725 USD
741% Upside
Vyne Therapeutics Inc Competitors:
Price Targets
600993
Mayinglong Pharmaceutical Group Co Ltd
38% Upside
688526
Wuhan Keqian Biology Co Ltd
43% Upside
300363
Porton Pharma Solutions Ltd
31% Upside
4016
Middle East Pharmaceutical Industries Company SJSC
12% Upside
300452
Anhui Sunhere Pharmaceutical Excipients Co Ltd
19% Upside

Revenue
Forecast

Revenue Estimate
Vyne Therapeutics Inc

For the last 8 years the compound annual growth rate for Vyne Therapeutics Inc's revenue is -4%. The projected CAGR for the next 4 years is 93%.

-4%
Past Growth
93%
Estimated Growth
Estimates Accuracy
-8%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Vyne Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Net Income
Forecast

Net Income Estimate
Vyne Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-91%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is VYNE's stock price target?
Price Target
3.315 USD

According to Wall Street analysts, the average 1-year price target for VYNE is 3.315 USD with a low forecast of 2.02 USD and a high forecast of 4.725 USD.

What is Vyne Therapeutics Inc's Revenue forecast?
Projected CAGR
93%

For the last 8 years the compound annual growth rate for Vyne Therapeutics Inc's revenue is -4%. The projected CAGR for the next 4 years is 93%.

Back to Top